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Abstract
The role of oral bacteria in the development of chemotherapy-related oral mucositis has not been fully elucidated. This study aimed to
investigate oral bacterial community diversity and dynamics in paediatric patients with malignancies in relation to the occurrence of oral
mucositis. Patients with malignancies (n = 37) and reference individuals without known systemic disorders (n = 38) were recruited. For
patients, oral bacterial samples were taken from mucosal surfaces both at the time of malignancy diagnosis and during chemotherapy. If oral
mucositis occurred, samples were taken from the surface of the mucositis lesions. Oral mucosal bacterial samples were also taken from
reference individuals. All samples were assessed using a 16S ribosomal RNA gene 454 pyrosequencing method. A lower microbial diversity
(p < 0.01) and a higher intersubject variability (p < 0.001) were found in patients as compared with reference individuals. At the time of
malignancy diagnosis (i.e. before chemotherapy) patients that later developed mucositis showed a higher microbial diversity (p < 0.05) and a
higher intersubject variability (p < 0.001) compared with those without mucositis. The change of bacterial composition during
chemotherapy was more pronounced in patients who later developed mucositis than those without mucositis (p < 0.01). In conclusion, we
found a higher microbial diversity at the time of malignancy diagnosis in patients who later develop oral mucositis and that these patients had
a more signiﬁcant modiﬁcation of the bacterial community by chemotherapy before the occurrence of mucositis. These ﬁndings may
possibly be of clinical importance in developing better strategies for personalized preventive management.
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All forms of cytostatic therapy give rise to side-effects that
have a major impact on the patients’ quality of life during
anticancer treatment. One of the side-effects is the inﬂamma-
tion of mucosal tissues, mucositis, which can involve the entire
alimentary tract. Oral mucositis is one of the most frequently
encountered forms and commonly occurs 7–10 days after the
administration of cytostatic drugs. Oral mucositis presents as
mucosal ulceration, bleeding and severe pain, which may
require the use of opiates and parenteral nutrition. The
mucositis-inﬂicted tissue damage also provides a port for the
invasion of host endogenous bacteria into the circulation,
causing bacteraemia and sepsis [1,2]. The patho-mechanisms of
chemotherapy-related oral mucositis have not been fully
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elucidated, although considerable progress has been made
during the last decade in deﬁning a cascade of destructive and
inﬂammatory events [3]. However, beyond this paradigm, the
association between mucositis and the commensal bacterial
microﬂora is so far poorly understood [4,5].
It is now well recognized that the diversity of microorgan-
isms colonizing the oral cavity has been greatly underestimated
[6]. Most of the bacterial species cause no harm under healthy
conditions. However, in patients with malignancies, the
delicate homeostasis between host defence and commensal
bacteria could be disturbed by the cancer itself, by the
cancer-related secondary immunodeﬁciency, or by prophylac-
tic antibacterials. The disrupted homeostasis might contribute
to the oral mucosal tissue breakdown following chemotherapy.
In addition, the chemotherapeutics can be bacteriostatic or
bactericidal, thus affecting the oral bacterial community [4,7,8].
However, no clear pattern regarding the changes in the oral
bacterial community and occurrence of oral mucositis can be
discerned from the literature, most likely due to the limited
number of studies published.
The impact of the bacterial community on the mucosal
integrity during chemotherapy cannot be fully understood
without comprehensive knowledge of the bacterial community
composition. The conventional culture-based or biochemical
methods can identify anticipated bacterial taxa, but lack the
capacity to detect non-cultivable microorganisms and the
possibility to address hitherto unknown taxa. However,
modern molecular methods for identifying bacterial taxa have
made it possible to assess a bacterial community with a
reduction in bias experienced in culture-based methods [9],
and furthermore, a massively parallel DNA sequencing tech-
nique, 454 pyrosequencing, has now greatly increased the
capacity to detect bacteria of low abundance [10,11].
In this study, we employed 16S rRNA gene 454 pyrose-
quencing, in order to determine the diversity and relative
abundance of oral mucosal bacterial taxa in paediatric patients
with malignancies. The oral bacteria were assessed at the time
of malignancy diagnosis prior to chemotherapy, during che-
motherapy and at the time of mucositis in an attempt to follow




This study was designed as a prospective longitudinal cohort
study. An ethics permit was granted by the Regional Ethical
Review Board, situated at Karolinska Institutet, Stockholm,
Sweden.
From November 2008 to December 2010, patients with
newly diagnosed malignancies (n = 109) were enrolled from
the Paediatric Cancer Ward, Astrid Lindgren Children’s
Hospital, Karolinska University Hospital, Stockholm, Sweden.
The exclusion criteria were as follows: (i) patients under
4 years of age or above 18 years of age, (ii) the treatment
protocol did not include cytostatic drugs, and/or (iii) patients
without national population registration number. Out of 60
patients that met inclusion criteria, 37 patients agreed to
participate in the present study. Age and gender-matched
children (n = 38), without any known systemic disorder and
who had not been treated with antibacterials 3 months prior
to the study, were recruited as reference individuals during
their routine dental visit to the Division of Paediatric
Dentistry, Department of Dental Medicine, Karolinska Insti-
tutet, Sweden. Assent and informed consent were obtained
from all the included children and their parents, respectively.
For the patients, data regarding age, gender and diagnosis
of malignancies were collected. Data including blood counts
of neutrophils, leukocytes and thrombocytes, and levels of
haemoglobin at the time of malignancy diagnosis, were
extracted from laboratory test reports. Oral health status,
including decayed, missing or ﬁlled teeth of permanent/
deciduous teeth (DMFT/dmft) and gingival bleeding index
(GBI) were assessed by the same dentist for all patients to
avoid inter-examiner difference. Oral care instructions,
including recommendation of a single 2.5 mg/mL benzyd-
amine-based mouth rinse for the period of chemotherapy,
were provided to the patients and parents. All patients were
followed during the entire cytostatic treatment. One dose of
the antibacterial cefotaxime was given intravenously to each
patient as prophylaxis before placing a central venous
catheter. The individual chemotherapeutic scheme and
antibacterial agents used for treating infections were
retrieved from medical charts and information regarding
the use of the mouth rinse was gathered from the parents.
The occurrence of oral mucositis was recorded and the
grade of oral mucositis was scored using the World Health
Organisation (WHO) system [12], which grades oral toxic
effects into ﬁve levels: grade 0, no change; grade 1,
soreness/erythema; grade 2, erythema, ulcers, can eat solids;
grade 3, ulcers, requires liquid diet only; grade 4, alimen-
tation not possible. A WHO grade > 1, which indicates
ulcerative mucositis, was considered as occurrence of oral
mucositis in the current study to avoid false-positive
diagnosis.
For the reference individuals, data including age, gender and
oral health status in terms of DMFT/dmft and GBI were
recorded. The same professional performed the oral health
evaluations for the patients and the reference individuals.
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Oral mucosal and mucositis samples
For the patients, oral mucosal samples were collected at two
time-points: ﬁrstly at the time of malignancy diagnosis (before
the administration of cytostatic drugs and use of mouth rinse;
however, after the single-dose prophylactic cefotaxime) and
secondly during chemotherapy prior to any sign of oral
mucositis (range from 5 to 84 days among patients after the
initiation of the entire chemotherapy, depending on the
chemotherapeutic schemes and hospital appointment). In
order to minimize the pain the mucosal samples were
collected using two paper strips (2 9 6 mm2) (PerioPaper,
Oralﬂow Inc., NY, USA) placed centrally on the lower lip and
on the bucca, respectively, for 15 seconds. For patients in
whom oral mucositis occurred, mucositis samples were taken
using paper strips placed on the top of the lesion and on the
surrounding mucosa. For the reference individuals, mucosal
samples were taken from the lower lip and bucca with the
same procedure as for the patients. All samples were
immediately stored at 20°C then transferred to 80°C
until analysis.
DNA extraction, 16S rRNA gene ampliﬁcation and
sequencing
The mucosal bacterial samples were analysed using 454 FLX
pyrosequencing according to previously described methods
[13,14] with minor modiﬁcations. After DNA extraction, lip and
buccal samples from the same individual at the same time-point
were pooled, and samples from mucositis lesions and the
surrounding mucosa from the same individual at the same
time-point were pooled with an equal volume of each DNA
extraction. The primer pairs for DNA ampliﬁcation were 341f
(5′-CCTACGGGNGGCWGCAG) with adaptor B and 805r
(5′-GACTACHVGGGTATCTAATCC) with adaptor A and a
speciﬁc sequence barcode consisting of seven nucleotides. The
PCR products were puriﬁed, pooled, ampliﬁed in PCR mixture
in oil emulsions, and sequenced using a two-lane PicoTiterPlate
on a Genome Sequencer FLX system (Roche, Switzerland) [15]
at the Science for Life Laboratory, Karolinska Institutet.
Sequence processing and taxonomic classiﬁcation
Sequence processing was carried out with the software
AmpliconNoise version 1.25 [16], correcting for errors
introduced in PCR and pyrosequencing, as well as removing
chimeric sequences. Denoised sequences were aligned and
sorted into operational taxonomic units (OTUs) at the 97%
similarity level using complete linkage clustering at the
Ribosomal Database Project [17].
In order to identify the taxonomical belonging of each OTU
cluster, the sequence aligner SINA was performed against the
SILVA SSU reference database version 111 [18], in which the
algorithm considers up to 40 of the best hits (≥ 70% identity)
and assigns taxonomy as the least common ancestor. If no hit
was found, the sequence was assigned as ‘unclassiﬁed’.
After the sequence noise reduction, 350 710 high-quality
sequences remained, with 376–4140 reads per sample (mean
2828). These sequences comprised 1613 OTUs clustered at a
97% similarity level. After taxonomic identiﬁcation, sequences
ascertained to be of bacterial origin consisted of 99% reads and
305 genera or the most detailed level of consensus taxonomy.
After a manual check of the taxonomic data, the sequences
assigned as ‘chloroplast’ and ‘mitochondria’, which are likely to
have been derived from eukaryotic cell organelles, were
excluded from the following statistical analysis.
Statistics
Analysis of the clinical data was carried out using the statistical
software package SPSS version 20. For the bacterial sequence
data with regard to relative abundance, the dominant taxa were
visualized as a heat map using MultiExperiment Viewer [19].
The microbial diversity of each sample was evaluated using the
Shannon diversity index (H’) based on an equal sub-sampling
level. The Shannon index, which takes both taxa richness and
the relative abundance into account, ranges from 0 (one species
presents) to about 4.5 (species are relatively evenly distrib-
uted). The R package vegan (http://CRAN.R-project.org/pack
age=vegan) was used to calculate the Shannon index and
signiﬁcance was tested using the Student’s t-test. The inter-
subject variability between each pair of samples was evaluated
on the platform Fast Unifrac [20] using normalized weighted
Unifrac distance, which ranges from 0 (100% OTUs shared,
two communities are identical) to 1 (0% OTUs shared, two
communities are completely distinctive). The Unifrac distance
was further interpreted and visualized using the principal
coordinate analysis (PCoA) on Fast Unifrac. Comparison of
each taxon between subject groups or between time-points
was made at the phylum level and the most detailed taxonomic
level using the R package edgeR [21,22]. The p values were
converted to false discovery rate (q value) to correct for
multiple testing. For all the statistical methods used, the level of
signiﬁcance was accepted at a = 0.05.
Results
Firstly, we compared the clinical parameters of the patients at
the time of malignancy diagnosis, which is before chemother-
apy, with those of the reference group. There was no
signiﬁcant difference regarding clinical characteristics in terms
of age, gender or oral health status between patients and
reference individuals (Table S1). The relative abundance of the
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dominant bacteria in all mucosal samples is presented in Fig.
S1. The diversity of the total bacterial community was lower in
the patients at the time of malignancy diagnosis compared with
the reference individuals (Fig. 1a). Furthermore, as shown in
Fig. 1(b,c), the intragroup Unifrac distance was higher in
patients than in the reference individuals, which indicates that
the patients were more heterogeneous among each other in
terms of their oral bacterial community. The intergroup
comparison of Unifrac distance showed a signiﬁcant difference
of the entire bacterial proﬁle between patients and reference
individuals; in addition, taxa with different relative abundance
between groups were identiﬁed (Table S2).
The clinical data and bacterial composition at the time-point
of malignancy diagnosis, prior to chemotherapy, were then
compared between patients who later developed oral muco-
sitis and those who did not. These two patient groups were
similar regarding age, gender and oral health status (Table 1).
However, lower levels of neutrophils, thrombocytes and
haemoglobin at the time of malignancy diagnosis were found in
individuals who later developed oral mucositis, most likely due
to the high number of cases with haematological malignancies
in this group (18 out of 25). As shown in Fig. 2(a), the total
microbial diversity, was signiﬁcantly higher in patients who
later developed mucositis compared with those who did not.
Regarding intersubject variability, at the time of malignancy
diagnosis, patients who later developed mucositis were more
dissimilar to each other than the no mucositis group (Fig. 2b,
c). To further identify the taxa that contribute to the
differences between groups, edgeR analysis showed that
patients who developed mucositis presented with higher levels
of the phyla Fusobacteria and Spirochaetes, compared with
those who did not develop mucositis (Table 2).
Between the initiation of chemotherapy and the sampling
time-point during chemotherapy, no difference was found
between patients who later developed mucositis and those
who did not regarding the use of antibacterial agents for
treating infections (Table S3). The antibacterials used include
cephalosporin, penicillin, aminoglycoside, thienamycin, tri-
methoprim-sulphamethoxazole and imidazole. The glycopep-
tide, which targets gram-positive bacteria, was not used prior
to the mucosal sampling. In addition, there was no difference
between the groups regarding the use of cytostatic regimens
and benzydamine-based mouth rinse, which both have
potential antibacterial effects [23–25] (Table S3). The microbial
diversity during chemotherapy did not change signiﬁcantly
compared with that at the time-point for malignancy diagnosis,
either for patients who developed mucositis (p 0.111) or for
those who did not (p 0.679). In comparing the variability
(a) (b)
(c)
FIG. 1. Comparison of the oral bacterial
community between reference individuals
and patients at the time of malignancy
diagnosis. The data represent 38
reference individuals and 37 patients. (a)
Microbial diversity in Shannon index
(mean  SD). (b) Principle coordinate
analysis. (c) Unifrac distance
(mean  SD), which was ﬁrstly
calculated for each subject group as
intragroup variability (left), and then the
combined data were compared with
intergroup variability (right). High values
of Unifrac distance indicate dissimilarity.
Student’s t-test was used. PC, principle
coordinate. *p < 0.05, **p < 0.01,
***p < 0.001.
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between the time-points, the change of bacterial community
composition was more evident in patients who later developed
mucositis than in those who did not (Fig. 3). In the comparison
regarding all bacterial taxa, the relative abundance of the
phylum Proteobacteria was decreased in the patients who
developed mucositis (Table 3).
The bacterial composition of samples from mucositis lesions
is included in Fig. S2, presenting a high variety of microbial
diversity (Shannon H’, median, 2.08; range, 0.37–3.71) and a
high intersample variability (Unifrac distance, mean  SD,
0.55  0.06). The comparison of each bacterial taxon was
made between all mucositis samples and all mucosal samples
(Table S4).
Discussion
The current study presents novel insights into the oral
mucosal bacterial dynamics in relation to chemother-
apy-related oral mucositis. We showed that at the time of
malignancy diagnosis, which is before chemotherapy, a more
heterogeneous bacterial community with higher microbial
diversity was found in the patients who later developed oral
mucositis compared with no mucositis group. In addition, we
found a more pronounced shift of the bacterial composition
after the initiation of chemotherapy in patients who later
developed oral mucositis compared with those who did not.
TABLE 1. Clinical characteristics of patients at the time of
malignancy diagnosis in patients who later developed oral












Age (year) 10.3 (4.4) 10.3 (4.3) 10.3 (4.8) 0.973
Gender (M/F) 28/9 19/6 9/3 1.000
DMFT/dmft 0.9 (1.8) 0.9 (1.6) 0.9 (2.3) 0.955
GBI (< 25%/> 25%) 33/4 22/3 11/1 1.000
Neutrophil (9 109/L) 4.0 (3.3) 2.6 (2.6) 6.7 (3.1) <0.001
Leukocyte (9 109/L) 23.9 (73.1) 30.4 (88.9) 10.2 (3.7) 0.438
Thrombocyte
(9 109/L)
246 (183) 193 (186) 356 (118) 0.009
Haemoglobin (g/L) 109 (17) 103 (15) 120 (15) 0.003
Diagnosis
ALL 12 12 0 –
AML 4 4 0 –
Non-Hodgkin
lymphoma
5 2 3 –
Hodgkin lymphoma 3 0 3 –
Brain tumour 5 1 4 –
Skeletal sarcoma 3 3 0 –
Rhabdomyosarcoma 3 2 1 –
Renal tumour 1 0 1 –
Carcinoma 1 1 0 –
SD, standard deviation; DMFT/dmft, decayed, missing or ﬁlled teeth of permanent/
deciduous teeth; GBI, gingival bleeding index; ALL, acute lymphoblastic leukaemia;
AML, acute myeloid leukaemia.




FIG. 2. Comparison of the oral bacterial
community at the time of malignancy
diagnosis between patients who later
developed oral mucositis (n = 25) and
patients who did not develop oral
mucositis (n = 12). (a) Microbial diversity
in Shannon index (mean  SD). (b)
Principle coordinate analysis. (c) Unifrac
distance (mean  SD), which was ﬁrstly
calculated for each subject group as
intragroup variability (left), and then the
combined data were compared with
intergroup variability (right). High values
of Unifrac distance indicate dissimilarity.
Student’s t-test was used. M, mucositis;
NM, no mucositis; PC, principle
coordinate; ns, no signiﬁcance. *p < 0.05,
***p < 0.001.
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The entire group of patients with malignancies exhibited a
less diverse and signiﬁcantly different bacterial community and
presented more dissimilarity to one another compared with
the reference children. This difference may be attributed to
the single-dose prophylactic cefotaxime administrated prior to
chemotherapy and potentially as a result of a compromised
host immunity and systemically altered inﬂammatory response
caused by the malignancies [26,27]. The inﬂammatory medi-
ators may impose a selective pressure resulting in bacteria that
have a greater ability to escape host phagocytic defence and a
higher tolerance against oxidative conditions, features that are
typical for human pathogens.
Upon comparison of microbial diversity before chemother-
apy, a higher level of diversity was detected in patients who
later developed mucositis compared with the group that did
not. Increased diversity of oral microbial communities has
previously been linked to several oral diseases, including
periodontal disease [28] and childhood caries [29]. Notably,
the taxon Capnocytophaga, which was more abundant in the
mucositis group, has been reported to be associated with
various tissue infections [30,31]. The accumulation of these
TABLE 2. Relative abundance (%) of taxa with different
levels at the time of malignancy diagnosis in patients who







p-Value q-ValuebMean SD Mean SD
Bacteroidetes




0.2 0.5 0.0 0.0 <0.001 0.001
Lactococcus 0.9 4.2 <0.1 0.1 <0.001 0.003
Fusobacteria 4.1 6.0 1.0 0.9 0.004 0.027
Spirochaetes 0.1 0.2 <0.1 < 0.1 0.003 0.027
aTaxonomies in phylum (boldface) and genus levels.




FIG. 3. Comparison of oral bacterial
community between the time-point of
malignancy diagnosis and during
chemotherapy. At malignancy diagnosis,
samples were taken from all patients.
During chemotherapy samples were
taken from 12 out of 25 patients in the
group that later developed oral mucositis
and 10 out of 12 patients in the group that
did not. (a and b) Principle coordinate
analysis. (c) Unifrac distance
(mean  SD), which was calculated
between the two time-points as
inter-time-point variability for each
subject group and compared. High values
of Unifrac distance indicate dissimilarity.
Student’s t-test was used. M, mucositis;
NM, no mucositis; PC, principle
coordinate. **p < 0.01.
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bacteria on the mucosal surface may possibly contribute to the
progression of mucositis and potentially to bacteraemia. The
bacterial community composition of the mucositis group was
found to be more heterogeneous than that of the no mucositis
group, which is consistent with the view that no single bacterial
taxon can be expected to be entirely accountable for affecting
the outcome of mucositis.
During chemotherapy, the bacterial community proﬁle was
altered in all patients. This is in line with studies on the
microbiota proﬁle of the intestine [32,33] and the oral cavity
[4,8] from chemotherapy-treated individuals or animal model.
The higher Unifrac distance in patients who developed
mucositis is largely driven by the changes of Proteobacteria
abundance during chemotherapy, which might be a conse-
quence of antibacterials used to treat systemic infections and
additionally a direct antimicrobial effect of cytostatic drugs
[23,24]. It also appeared that the no mucositis group was less
modiﬁed by the chemotherapeutic treatment, which might
indicate a beneﬁcial effect of a higher microbial stability.
Interestingly, our results show that the complexity of oral
bacteria in terms of Shannon diversity does not change after
the initiation of chemotherapy in either patient group, which is
contrary to a previous study using Sanger-based sequencing
[34]. These opposing results are most likely a reﬂection of the
different methods applied. In order to determine diversity it is
important to be able to detect low abundant taxa and the 454
pyrosequencing technique has a higher sensitivity in this
respect.
The genus Streptococcus, which has been reported to
increase following chemotherapy [35], showed an elevated
mean value in patients who later developed mucositis in our
study; however, it was not statistically conﬁrmed. The level
of Staphylococci was found to be increased during treatment
in the group that later developed mucositis; however, this
was due to a surprisingly elevated level in one patient. The
previously suggested mucositis-associated species, including
Enterococcus [8], Escherichia [4], Porphyromonas [7] and
Pseudomonas [4], were not statistically conﬁrmed in terms
of relative abundance in the present study, which may in
part be attributed to methodological differences. It is
noticed that because of the limited number of patients
from each malignant diagnosis in this study, it is not possible
to clarify the question of whether the individual bacterial
proﬁle among patients receiving identical treatment is
related to oral mucositis. Large cohort studies that are
controlled for the chemotherapy scheme are thus needed in
the future.
The breakdown of the mucosal barrier provides a port for
the invasion of endogenous bacteria [30,31,36–39]. In this
study, we identiﬁed a distinctive bacterial composition from
the mucositis lesions compared with all the mucosal samples
from the lip and bucca. Within the dominant bacteria from
the lesions, an increased abundance of Lactobacillus, Myco-
plasma and Peptostreptococcus was identiﬁed. Both Myco-
plasma and Peptostreptococcus are recognized as signiﬁcant
pathogenic microorganisms due to their resistance to
common antibacterial agents. While bacteria belonging to
the genus Lactobacillus are well known for contributing to
deep tooth decay in the oral cavity, their facultative
anaerobic characteristics and tolerance to oxidative condi-
tions may also account for the growth in the lesions of
mucosal tissues. Overall, the increase of these potential
pathogens in mucosal ulcers might be the effect of the ulcers
representing a different niche in which virulent pathogens can
compete successfully with the resident bacteria, in addition
to the effect of the empirical antimicrobial therapy admin-
istered.
Importantly, although beyond the scope of this study,
Candida and viruses have long been indicated to play a role in
oral mucositis and subsequent systemic infection [8,40].
Therefore, studies with a focus on their relation to the
commensal bacteria, including bacteriophages, will be required
to clarify the role of the entire oral microbiota in the
pathogenesis of mucositis.
TABLE 3. Relative abundance (%) of
taxa with different levels between
the time-point of malignancy diag-






p-Value q-ValuecMean SD Mean SD
Mucositis (n = 25)b
Firmicutes
Staphylococcus 0.1 0.1 6.7 20.9 <0.001 <0.001
Proteobacteria 21.9 18.1 8.3 7.0 0.001 0.015
Derxia 3.9 8.4 0.4 0.5 0.001 0.027
No mucositis (n = 12)b
Proteobacteria
Xanthomonas 0.0 0.0 0.2 0.7 <0.001 0.003
aTaxonomies in phylum (boldface) and genus levels.
bDuring chemotherapy samples were taken from 12 patients in the mucositis group and 10 patients in the no mucositis
group.
cq value was used to determine statistical signiﬁcance.
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Conclusions
Powered by high-throughput 454 pyrosequencing, the current
study indicates that at the time of malignancy diagnosis,
patients who later developed oral mucositis showed higher
oral mucosal microbial diversity and were more heteroge-
neous among one another compared with those who did not
develop mucositis. A more pronounced modiﬁcation of the
bacterial community by chemotherapy was detected in
patients who later developed oral mucositis, indicating that
oral microbial stability might be beneﬁcial. These ﬁndings might
contribute to the development of better prophylactic treat-
ments and improved intervention protocols for oral mucositis,
tailored to the individual patient.
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